FIELD: medicine, pharmacy, pharmaceutical technology.
SUBSTANCE: invention relates to pharmaceutical compositions as tablets, namely, to a tablet preparing by direct pressing and comprising 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or its pharmaceutically acceptable salts as an active component taken in the amount from 5 to 140 mg as measured for a pure acid, an excipient, a dry binding agent, a disintegrating agent and a lubricating substance, and to a method for its preparing. As an excipient the claimed composition comprises the combination of at least two recipients but with exception of lactose, and it comprises 20-80 weight% of excipient chosen from group comprising microcrystalline or powder-like cellulose and calcium hydrophosphate, and 0.001-50 weight% of one or more recipients chosen from group comprising mannitol and phosphates or hydrophosphates of alkaline or alkaline-earth metals. As a disintegrating agent the composition comprises maize starch taken in the amount 7-15%. The content of lubricating agent is 1%.
EFFECT: improved preparing method of tablet.
3 cl, 19 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
SOLID PHARMACEUTICAL COMPOSITION FOR PERORAL USING COMPRISING DERIVATIVE OF BIS-PHOSPHONIC ACID | 2001 |
|
RU2288705C2 |
DOSAGE FORM CONTAINING DESLORATADINE AND METHOD FOR PRODUCING IT | 2013 |
|
RU2550958C2 |
COMPOSITION OF BIS-PHOSPHONIC ACIDS FOR WET GRANULATION | 1995 |
|
RU2149003C1 |
METHOD OF MAKING TABLET CONTAINING BISPHOSPHONIC ACIDS, SOLID MEDICINAL FORM AND PHARMACEUTICAL COMPOSITION | 1993 |
|
RU2148405C1 |
PHARMACEUTICAL COMPOSITION CONTAINING DESLORATADINE (VERSIONS) | 2013 |
|
RU2537169C1 |
SODIUM IBUPROFEN TABLETS AND METHODS FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING SODIUM IBUPROFEN | 2010 |
|
RU2715680C2 |
ORAL SOLID DOSAGE FORM AND METHOD OF TREATING | 2011 |
|
RU2480210C1 |
PHARMACEUTICAL PREPARATIONS WITH FIXED COMBINATION OF ANALGESIC AND ANTISPASMODIC AGENTS DOSES | 2015 |
|
RU2704613C2 |
PHARMACEUTICAL COMPOSITION FOR SLEEP DISORDERS PREVENTION AND TREATMENT | 2016 |
|
RU2620855C1 |
PHARMACEUTICAL COMPOSITIONS COMPRISING 5,8,14-TRIAZATETRACYCLO[10,3,1,0(2,11),0(4,9)HEXADECA-2( 11),3,5,7,9-PENTAENE | 2002 |
|
RU2272629C2 |
Authors
Dates
2006-07-10—Published
2001-06-29—Filed